CN112494597A - 用于辅助生长的组合物及制备方法 - Google Patents
用于辅助生长的组合物及制备方法 Download PDFInfo
- Publication number
- CN112494597A CN112494597A CN201910791605.XA CN201910791605A CN112494597A CN 112494597 A CN112494597 A CN 112494597A CN 201910791605 A CN201910791605 A CN 201910791605A CN 112494597 A CN112494597 A CN 112494597A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- radix ophiopogonis
- steps
- carrot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000012010 growth Effects 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 241000282414 Homo sapiens Species 0.000 claims abstract description 85
- 241000405414 Rehmannia Species 0.000 claims abstract description 81
- 210000002826 placenta Anatomy 0.000 claims abstract description 76
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 73
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 64
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 64
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 64
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 64
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 64
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 64
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 64
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 64
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 64
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 64
- 244000000626 Daucus carota Species 0.000 claims abstract description 64
- 235000002767 Daucus carota Nutrition 0.000 claims abstract description 64
- 241000237502 Ostreidae Species 0.000 claims abstract description 61
- 235000020636 oyster Nutrition 0.000 claims abstract description 61
- 235000001188 Peltandra virginica Nutrition 0.000 claims abstract description 52
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 33
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 33
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 33
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 24
- 210000000582 semen Anatomy 0.000 claims abstract description 13
- 244000248825 Peltandra virginica Species 0.000 claims abstract 9
- 244000182216 Mimusops elengi Species 0.000 claims abstract 2
- 241001092040 Crataegus Species 0.000 claims description 65
- 235000013399 edible fruits Nutrition 0.000 claims description 42
- 244000241838 Lycium barbarum Species 0.000 claims description 33
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 33
- 235000015468 Lycium chinense Nutrition 0.000 claims description 32
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 30
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 30
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 29
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 13
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 244000248557 Ophiopogon japonicus Species 0.000 claims description 10
- 240000008866 Ziziphus nummularia Species 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 6
- 239000011812 mixed powder Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 229930195210 Ophiopogon Natural products 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 244000171085 Polyporus umbellatus Species 0.000 claims description 3
- 235000004837 Polyporus umbellatus Nutrition 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 210000003813 thumb Anatomy 0.000 claims description 3
- 235000004879 dioscorea Nutrition 0.000 abstract description 42
- 238000010521 absorption reaction Methods 0.000 abstract description 18
- 206010067482 No adverse event Diseases 0.000 abstract description 16
- 230000008901 benefit Effects 0.000 abstract description 16
- 231100000957 no side effect Toxicity 0.000 abstract description 16
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 240000005717 Dioscorea alata Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 79
- 244000197580 Poria cocos Species 0.000 description 64
- 241000699670 Mus sp. Species 0.000 description 51
- 244000281702 Dioscorea villosa Species 0.000 description 42
- 239000003814 drug Substances 0.000 description 37
- 240000002624 Mespilus germanica Species 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 31
- 230000006870 function Effects 0.000 description 30
- 210000004185 liver Anatomy 0.000 description 28
- 150000004804 polysaccharides Chemical class 0.000 description 28
- 230000001737 promoting effect Effects 0.000 description 28
- 229920001282 polysaccharide Polymers 0.000 description 27
- 239000005017 polysaccharide Substances 0.000 description 27
- 238000011160 research Methods 0.000 description 27
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 22
- 239000008280 blood Substances 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 20
- 241000700159 Rattus Species 0.000 description 19
- 230000036737 immune function Effects 0.000 description 19
- 210000000952 spleen Anatomy 0.000 description 19
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 18
- 239000011575 calcium Substances 0.000 description 18
- 229910052791 calcium Inorganic materials 0.000 description 18
- 235000001465 calcium Nutrition 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 18
- 230000002708 enhancing effect Effects 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 230000007812 deficiency Effects 0.000 description 16
- 239000000284 extract Substances 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 14
- 229940024606 amino acid Drugs 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 14
- 150000001746 carotenes Chemical class 0.000 description 14
- 235000005473 carotenes Nutrition 0.000 description 14
- 230000036039 immunity Effects 0.000 description 14
- 230000000144 pharmacologic effect Effects 0.000 description 14
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 14
- 230000009471 action Effects 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 210000002540 macrophage Anatomy 0.000 description 13
- 230000035755 proliferation Effects 0.000 description 13
- 229910052742 iron Inorganic materials 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 229960003284 iron Drugs 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 10
- 208000004880 Polyuria Diseases 0.000 description 10
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 10
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 206010022437 insomnia Diseases 0.000 description 10
- 230000015654 memory Effects 0.000 description 10
- 230000000242 pagocytic effect Effects 0.000 description 10
- 235000019155 vitamin A Nutrition 0.000 description 10
- 239000011719 vitamin A Substances 0.000 description 10
- 229940045997 vitamin a Drugs 0.000 description 10
- 239000011701 zinc Substances 0.000 description 10
- 229910052725 zinc Inorganic materials 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 230000004438 eyesight Effects 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 230000001976 improved effect Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 229960003080 taurine Drugs 0.000 description 9
- 210000001541 thymus gland Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- -1 kininase Proteins 0.000 description 8
- 230000007958 sleep Effects 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 239000011573 trace mineral Substances 0.000 description 8
- 235000013619 trace mineral Nutrition 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000035619 diuresis Effects 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 230000003394 haemopoietic effect Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 206010021143 Hypoxia Diseases 0.000 description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- 210000000683 abdominal cavity Anatomy 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 239000000469 ethanolic extract Substances 0.000 description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 108010006464 Hemolysin Proteins Proteins 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 5
- 230000007969 cellular immunity Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 239000003228 hemolysin Substances 0.000 description 5
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000003393 splenic effect Effects 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- 102100035419 DnaJ homolog subfamily B member 9 Human genes 0.000 description 4
- 101710173651 DnaJ homolog subfamily B member 9 Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 241001247821 Ziziphus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000002929 anti-fatigue Effects 0.000 description 4
- 230000000949 anxiolytic effect Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 230000007661 gastrointestinal function Effects 0.000 description 4
- 230000004727 humoral immunity Effects 0.000 description 4
- 230000007365 immunoregulation Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000002398 materia medica Substances 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 230000035900 sweating Effects 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- 150000003648 triterpenes Chemical class 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 235000019750 Crude protein Nutrition 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 102100038803 Somatotropin Human genes 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 239000006286 aqueous extract Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 230000002457 bidirectional effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical group N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 239000000122 growth hormone Substances 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000013923 monosodium glutamate Nutrition 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000003169 placental effect Effects 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000037322 slow-wave sleep Effects 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000282461 Canis lupus Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 2
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 235000014493 Crataegus Nutrition 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 241000208175 Daucus Species 0.000 description 2
- 206010014025 Ear swelling Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 2
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241000218164 Menispermaceae Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 102000004576 Placental Lactogen Human genes 0.000 description 2
- 108010003044 Placental Lactogen Proteins 0.000 description 2
- 239000000381 Placental Lactogen Substances 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 2
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 244000299790 Rheum rhabarbarum Species 0.000 description 2
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 206010048259 Zinc deficiency Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000010208 anthocyanin Nutrition 0.000 description 2
- 239000004410 anthocyanin Substances 0.000 description 2
- 229930002877 anthocyanin Natural products 0.000 description 2
- 150000004636 anthocyanins Chemical class 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- VNONINPVFQTJOC-ZGXDEBHDSA-N dioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O VNONINPVFQTJOC-ZGXDEBHDSA-N 0.000 description 2
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000007087 memory ability Effects 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 239000002366 mineral element Substances 0.000 description 2
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 2
- 239000004223 monosodium glutamate Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 2
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 238000010181 skin prick test Methods 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229930002600 steroidal saponin Natural products 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- HDDLVZWGOPWKFW-UHFFFAOYSA-N trimethyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound COC(=O)CC(O)(C(=O)OC)CC(=O)OC HDDLVZWGOPWKFW-UHFFFAOYSA-N 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WYUFTYLVLQZQNH-UHFFFAOYSA-N 1-Ethyl-D-galactoside Natural products CCOC1OC(CO)C(O)C(O)C1O WYUFTYLVLQZQNH-UHFFFAOYSA-N 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- RANQPHKSRUUPKK-UHFFFAOYSA-N 3-O-[alpha-L-arabinofuranosyl-(1->2)-O-{beta-D-glucopyranosyl-(1->3)}-(alpha-L-arabinopyranosyl)]jujubogenin Natural products CC(C)=CC1CC(C)(O)C2C3CCC4C5(C)CCC(OC6OCC(O)C(OC7OC(CO)C(O)C(O)C7O)C6OC6OC(CO)C(O)C6O)C(C)(C)C5CCC4(C)C33COC2(C3)O1 RANQPHKSRUUPKK-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101710189683 Alkaline protease 1 Proteins 0.000 description 1
- 101710154562 Alkaline proteinase Proteins 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 244000068687 Amelanchier alnifolia Species 0.000 description 1
- 235000009027 Amelanchier alnifolia Nutrition 0.000 description 1
- 235000007087 Amelanchier canadensis Nutrition 0.000 description 1
- 235000001428 Amelanchier x grandiflora Nutrition 0.000 description 1
- 102100039160 Amiloride-sensitive amine oxidase [copper-containing] Human genes 0.000 description 1
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 102100021253 Antileukoproteinase Human genes 0.000 description 1
- 101710170876 Antileukoproteinase Proteins 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 229930190007 Baccatin Natural products 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 101710112538 C-C motif chemokine 27 Proteins 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 101000972837 Canis lupus familiaris Glutamate receptor ionotropic, NMDA 1 Proteins 0.000 description 1
- 208000009447 Cardiac Edema Diseases 0.000 description 1
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
- 241000237501 Crassostrea Species 0.000 description 1
- 235000000314 Crataegus calpodendron Nutrition 0.000 description 1
- 241001504664 Crossocheilus latius Species 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- PGZCJOPTDHWYES-UHFFFAOYSA-N Dehydroabietic acid methyl ester Natural products CC(C)C1=CC=C2C3(C)CCCC(C(=O)OC)(C)C3CCC2=C1 PGZCJOPTDHWYES-UHFFFAOYSA-N 0.000 description 1
- 229930195236 Digitoside Natural products 0.000 description 1
- 235000005903 Dioscorea Nutrition 0.000 description 1
- 235000000504 Dioscorea villosa Nutrition 0.000 description 1
- 241000234272 Dioscoreaceae Species 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- WYUFTYLVLQZQNH-JAJWTYFOSA-N Ethyl beta-D-glucopyranoside Chemical compound CCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WYUFTYLVLQZQNH-JAJWTYFOSA-N 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- 241000186871 Lactobacillus murinus Species 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101800001072 Protein 1A Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108010016283 TCF Transcription Factors Proteins 0.000 description 1
- 102000000479 TCF Transcription Factors Human genes 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 241001506047 Tremella Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 229960004266 acetylcholine chloride Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006400 anxiety behaviour Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 238000003321 atomic absorption spectrophotometry Methods 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 229910001422 barium ion Inorganic materials 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 108010042362 beta-Lipotropin Proteins 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 1
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000009096 changqing Substances 0.000 description 1
- 238000004182 chemical digestion Methods 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 1
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 229940108605 cyclophosphamide injection Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000013229 diet-induced obese mouse Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000551 effect on thymus Effects 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002137 ergosterols Chemical class 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 238000005242 forging Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 229930192286 jujuboside Natural products 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- PGZCJOPTDHWYES-HMXCVIKNSA-N methyl (1r,4as,10ar)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylate Chemical compound CC(C)C1=CC=C2[C@@]3(C)CCC[C@](C(=O)OC)(C)[C@@H]3CCC2=C1 PGZCJOPTDHWYES-HMXCVIKNSA-N 0.000 description 1
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000009941 northern hawthorn Nutrition 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000005789 organism growth Effects 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 1
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 229940078042 polysaccharide iron complex Drugs 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004938 stress stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 230000036977 tonic contraction Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- RMRCNWBMXRMIRW-WYVZQNDMSA-L vitamin b12 Chemical compound N([C@@H]([C@@]1(C)[C@@](C)(CC(N)=O)[C@H](CCC(N)=O)\C(N1[Co+]C#N)=C(/C)\C1=N\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NCC(C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO RMRCNWBMXRMIRW-WYVZQNDMSA-L 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 239000008883 yougui Substances 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Marine Sciences & Fisheries (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本申请公开了一种用于辅助生长的组合物的制备方法,该用于辅助生长的组合物,包括以下组分:紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜。本申请的用于辅助生长的组合物,通过紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜的协同作用,可促进人体吸收,辅助适龄人群生长,无副作用,无不良反应,安全可靠。
Description
技术领域
本申请涉及保健食品技术领域,特别是涉及用于辅助生长的组合物的制备方法。
背景技术
身高一般以厘米(cm)作单位,也较经常用“米”(m)。身高是对人体纵向部分的长度,源于人体的纵向生长,受遗传因素的影响较大。女孩比男孩身高发育的早,在12-13岁为快速增长时期,到19-23岁开始停止增长,而男孩身高发育的晚,在15-16岁为快速增长时期,到20-24岁停止增长,四肢长骨和脊椎骨均已完成骨化,身高就停止增长了。影响身高的因素很多,如遗传、营养、体育运动、环境、生活习惯、民族种族、内分泌、性成熟早晚(初潮年龄18岁比11岁者平均高出5厘米)、远近亲婚配、医学进步等等。
目前,用于促进生长的药物、复合食品、维生素种类众多,不同程度都添加了刺激生长的动物激素,在促进生长的同时具有副作用和不良反应,不适合长期食用。因此,需要一种无副作用,无不良反应的中药组合物。
发明内容
本申请的目的在于克服上述问题或者至少部分地解决或缓解上述问题。
根据本申请的第一方面,提供了一种用于辅助生长的组合物,包括以下组分:紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜。
可选地,所述紫河车:1~20重量份,所述酸枣仁:1~20重量份,所述伏苓:1~22重量份,所述淮山药:1~22重量份,所述枸杞子:1~20重量份,所述山楂:1~20重量份,所述麦冬:1~20重量份,所述熟地黄:1~20重量份,所述牡蛎:1~21重量份,所述胡萝卜:1~25重量份。
可选地,所述紫河车:3~18重量份,所述酸枣仁:3~18重量份,所述伏苓:2~20重量份,所述淮山药:3~21重量份,所述枸杞子:2~19重量份,所述山楂:3~18重量份,所述麦冬:3~19重量份,所述熟地黄:2~18重量份,所述牡蛎:2~19重量份,所述胡萝卜:3~23重量份。
可选地,所述紫河车:5~16重量份,所述酸枣仁:5~16重量份,所述伏苓:4~18重量份,所述淮山药:5~19重量份,所述枸杞子:4~17重量份,所述山楂:5~16重量份,所述麦冬:5~17重量份,所述熟地黄:4~17重量份,所述牡蛎:4~18重量份,所述胡萝卜:5~21重量份。
可选地,所述紫河车:7~14重量份,所述酸枣仁:7~14重量份,所述伏苓:6~16重量份,所述淮山药:7~17重量份,所述枸杞子:6~16重量份,所述山楂:7~15重量份,所述麦冬:6~16重量份,所述熟地黄:6~15重量份,所述牡蛎:6~16重量份,所述胡萝卜:6~18重量份。
可选地,所述紫河车:9~12重量份,所述酸枣仁:9~12重量份,所述伏苓:7~14重量份,所述淮山药:8~16重量份,所述枸杞子:7~15重量份,所述山楂:8~13重量份,所述麦冬:7~14重量份,所述熟地黄:7~14重量份,所述牡蛎:8~15重量份,所述胡萝卜:7~16重量份。
可选地,所述紫河车:10~11重量份,所述酸枣仁:9~12重量份,所述伏苓:9~12重量份,所述淮山药:10~14重量份,所述枸杞子:9~13重量份,所述山楂:10~11重量份,所述麦冬:9~12重量份,所述熟地黄:9~13 重量份,所述牡蛎:10~13重量份,所述胡萝卜:9~13重量份。
可选地,所述紫河车:10.5重量份,所述酸枣仁:10.5重量份,所述伏苓: 11重量份,所述淮山药:12重量份,所述枸杞子:11重量份,所述山楂:10.5 重量份,所述麦冬:11重量份,所述熟地黄:10重量份,所述牡蛎:11.5重量份,所述胡萝卜:12重量份。
根据本申请的第二方面,提供了一种用于辅助生长的组合物的制备方法,包括以下步骤:
称取步骤:按照第一方面所述的组合物称取紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜;
清洗步骤:将所述紫河车、所述酸枣仁、所述伏苓、所述淮山药、所述枸杞子、所述山楂、所述麦冬、所述熟地黄、所述牡蛎和所述胡萝卜分别清洗备用;
烘干步骤:将清洗后的所述紫河车、所述酸枣仁、所述伏苓、所述淮山药、所述枸杞子、所述山楂、所述麦冬、所述熟地黄、所述牡蛎和所述胡萝卜分别进行烘干;
粉碎步骤:将烘干后的所述紫河车、所述酸枣仁、所述伏苓、所述淮山药、所述枸杞子、所述山楂、所述麦冬、所述熟地黄、所述牡蛎和所述胡萝卜分别进行粉碎;
混合步骤:将粉碎的所述紫河车、所述酸枣仁、所述伏苓、所述淮山药、所述枸杞子、所述山楂、所述麦冬、所述熟地黄、所述牡蛎和所述胡萝卜放到器皿中混合,形成混合粉;
过筛步骤:将所述混合粉放入100目筛去除大颗粒,获得标准粉。
本申请的用于辅助生长的组合物,通过紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜的协同作用,可促进人体吸收,辅助适龄人群生长,无副作用,无不良反应,安全可靠。
根据下文结合附图对本申请的具体实施例的详细描述,本领域技术人员将会更加明了本申请的上述以及其他目的、优点和特征。
附图说明
后文将参照附图以示例性而非限制性的方式详细描述本申请的一些具体实施例。附图中相同的附图标记标示了相同或类似的部件或部分。本领域技术人员应该理解,这些附图未必是按比例绘制的。附图中:
图1是根据本申请一个实施例的用于辅助生长的组合物的制备方法的流程图。
具体实施方式
本申请的第一方面,提供了一种用于辅助生长的组合物,包括以下组分:紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜。
一、紫河车的药理作用:
补气,养血,益精,增强免疫力,促进生长。李时珍的《本草纲目》中记载:“儿孕胎中,脐系于母,胎系母脊,受母之荫,父精母血,相合而成。虽后天之形,实得先天之气,显然非他金石草木之类所比。其滋补之功极重,久服耳聪目明,须发乌黑,延年益寿”。紫河车内的人胎盘催乳素与人垂体生长素的化学结构相关,有免疫交叉反应。
1、紫河车的化学成分现代研究表明,紫河车主要含有免疫球蛋白,干扰素,胨,胎盘肽,促脂素,氨基酸,促黑素,阿片肽,胆碱,磷脂,红细胞生成素,内啡肽,白细胞介素,表皮生长因子,肿瘤坏死因子,巨球蛋白抑制因子,转化生长因子,类胰岛细胞生长因子,促细胞生长因子,纤维蛋白稳定因子,各种酶(膜基质金属蛋白酶,碱性磷酸酶,库尼特型蛋白酶抑制剂,丝氨酸棕榈转移酶,人胎盘谷胱甘肽s-转移酶,溶菌酶,组胺酶,催产素酶,激肽酶,胰蛋白酶,球蛋白酶),激素(女性激素,助孕酮,内固醇激素,促性腺激素,促肾上腺皮质激素,人绒毛膜促性腺激素,人胎盘催乳素,人绒毛膜促甲状腺素,促性腺激素释放激素,促肾上腺皮质激素释放激素,促甲状腺激素释放激素,雌二醇,雌酮,孕酮,胎盘雄激素,抑素等),维生素(钙,铁,锌,镁,维生素b12,乙酰胆碱),胶原蛋白,氨基酸及一些与凝血机能相关的因子。
2、紫河车的疗效:
2.1免疫调节作用;
胎盘肽和胎盘转移因子,均具有免疫双向调节作用,近年报道胎盘肽是一种较好的免疫调节和增强剂,具有明显提高机体免疫功能的作用。苏是煌,林志和在《紫河车对小鼠细胞免疫功能的调节作用》的研究中发现,胎盘粉制剂能使小鼠单核巨噬细胞的吞噬指数明显提高,明显增加免疫器官重量,对小鼠脾淋巴细胞转化反应具有较强的促进作用。
2.2抗感染作用;
在近些年的研究中发现紫河车中的球蛋白,所含的干扰素能预防和控制多种病毒感染。
2.3营养和生长因子作用;
王亮以基础培养基,培养新生小鼠的表皮基底细胞,经过对比实验,确认人胎盘组织提取液具有营养和生长因子作用,能促进细胞增殖和新陈代谢。
2.4抗缺氧耐疲劳作用;
章生银通过给小鼠灌服紫河车煎液,观察显著增加小鼠负荷游泳时间变化,表明紫河车能显著延长小鼠耐缺氧时间,显示紫河车的大补元气和气血双补的传统功效。
二、酸枣仁:
为鼠李科植物酸枣的种子。秋季果实成熟时采收,将果实浸泡一宿,搓去果肉,捞出,用石碾碾碎果核,取出种子,晒干。功能主治为:养肝,宁心,安神,敛汗。治虚烦不眠,惊悸怔忡,烦渴,虚汗。①《本经》:主心腹寒热,邪结气聚,四肢酸疼,湿痹。②《别录》:主烦心不得眠,脐上下痛,血转久泄,虚汗烦渴,补中,益肝气,坚筋骨,助阴气,令人肥健。③《药性论》:主筋骨风,炒末作汤服之。④《本草拾遗》:睡多生使,不得睡炒熟。⑤王好古:治胆虚不眠,寒也,炒服;治胆实多睡,热也,生用。⑥《本草汇言》:敛气安神,荣筋养髓,和胃运脾。⑦《本草再新》:平肝理气,润肺养阴,温中利湿,敛气止汗,益志定呵,聪耳明目。
1、酸枣仁化学成分:
含多量脂肪油和蛋白质,并有两种甾醇:一种为C26H42O2,熔点288~290℃,易溶于醇;另一种的熔点为259~260℃,易溶于氯仿。又谓酸枣仁主含两种三萜化合物:白桦脂醇、白桦脂酸。另含酸枣皂甙,甙元为酸枣甙元,水解所得到的厄北林内酯是皂甙的第二步产物。酸枣仁还含多量维生素C。
2、酸枣仁药理分析:
2.1促进生长;
人体身高的决定性因素是生长激素,生长激素的分泌主要与睡眠,尤其是慢波睡眠(slow wave sleep,SWS)有关。将酸枣仁提取物0.320mg·g-1给予小白鼠灌胃,观察药物促进骨骼增高作用。同时给予大白鼠酸枣仁提取物 0.220mg·g-1灌胃,检测脑组织5-羟色胺受体蛋白1A(5-hydroxytryptamine 1A receptor,5-HT1AR)含量和活性、生长激素分泌情况及对慢波睡眠时间的影响。结果:①酸枣仁提取物组小白鼠体长明显优于对照组;②用药组较对照组总睡眠时间明显延长,清醒时间减少;③药物可以明显促进大白鼠体内生长激素分泌,明显高于对照组;④酸枣仁提取物可以显著促进脑组织5-HT1AR活性。结论:酸枣仁提取物可以促进骨骼增长。
2.2镇静、催眠作用;
酸枣仁是养心安神中药,药食同源之上品,是治疗各种失眠的常用中药。酸枣仁所含的化学成分主要有皂苷类、黄酮类、生物碱类、三萜类、甾体类、脂肪酸类、挥发油类等。研究表明,酸枣仁皂苷具有镇静催眠作用。
酸枣仁煎剂给大白鼠口服或腹腔注射均表现镇静及嗜眠,无论白天或黑夜,正常状态或咖啡,因引起的兴奋状态,酸枣仁均能表现上述作用,小白鼠口服时的镇静指数为1.95,与巴比妥类药物表现协同作用,酸枣仁连续应用6天,可使动物睡眠变浅,持续时间缩短,即产生耐受性,但停药1周后可消失。口服酸枣仁可使防御性运动性条件反射次数显着减少,内抑制扩散,条件反射消退,抑制猫由吗啡引起的躁狂现象。
三、茯苓:
茯苓为多孔菌科真菌茯苓Poria cocos(Schw.)Wolf的干燥菌核(《中国药典》2010年版一部收载),为常用中药,具有利水渗湿、健脾、宁心之功效,用于水肿尿少、痰饮眩悸、脾虚食少、便溏泄泻、心神不安和惊悸失眠等症。在临床上具有广泛的应用。
1、茯苓化学成分研究;
三萜类化合物,目前从茯苓中分离得到三萜类成分40个。二萜类化合物,从茯苓中分离得到1个三环二萜类化合物,为去氢松香酸甲酯。甾醇类化合物,从茯苓中分离得到麦角甾醇类化合物10个。其他类化合物,从茯苓中也分离得到一些其他类化合物,包括乙基-β-D-吡喃葡萄糖苷、L-尿苷、柠檬酸三甲酯、R-苹果酸二甲酯、胡萝卜苷。
2、茯苓病理作用分析:
2.1利水消肿作用;
茯苓的利水作用,是把多余水分从身体各组织中收集起来,运到肾脏,排出体外。茯苓对水滞留型体质效果值得肯定,这被称为茯苓的特异利尿作用。
李森等研究发现茯苓水煎液(2.5、5、10g/kg)对生理盐水负荷大鼠、小鼠灌胃给药有较显著的利尿作用,且作用持久。其中茯苓水煎液(5、10g/kg) 能使动物尿中K+排出量较阴性对照组显著升高,Na+/K+较阴性对照组显著降低。宁康健等研究表明静注茯苓水煎醇沉液(1.5、2.5g/kg)能明显增加家兔尿量,其中2.5g/kg的剂量在给药10min内尿量出现高峰,表明茯苓对家兔具有明显的利尿作用,并且存在一定程度的正向量效关系。
康爱秋等在原方的基础上仅改变云苓的剂量(10、15、20、30、50、75、 100g)来治疗心源性水肿55例,结果发现茯苓剂量在30g以上才能达到利尿的作用,且100g/d时利尿作用最强,提示茯苓利水渗湿的作用具有量效关系,且随着剂量的增加而增强。
2.2免疫调节作用;
国内外学者对茯苓增强免疫功能进行了较多的研究。段超等通过银耳、茯苓、绞股蓝对小鼠免疫功能和清除自由基的作用证明,茯苓能增强小鼠特异性细胞免疫功能。
研究显示,茯苓水提物、碱提物和醇提物都能促进小鼠腹腔内巨噬细胞的吞噬指数和吞噬百分率,显著增加小鼠血清内免疫因子IL-2和TNF-的含量,使胸腺及脾脏的质量增加。结果表明,茯苓发挥免疫调节作用的物质基础主要为三萜类、水溶性多糖和酸性多糖。
茯苓多糖200g或1000g与流感病毒灭活疫苗共同给小鼠肌肉注射免疫,结果显示,茯苓多糖能增强流感灭活疫苗的免疫效果,且呈剂量依赖关系;并提高小鼠抗致死量流感病毒攻击的能力,其免疫增强效果与氢氧化铝相当。茯苓素对由PHA、LPS和ConA诱导的淋巴细胞转化有显著的抑制作用,且呈剂量依赖关系;小剂量茯苓素对L615小鼠的血清溶血素水平及脾细胞抗体产生有刺激作用,稍大剂量则表现为抑制,且茯苓素达到一定剂量后再增加剂量,其抑制强度不再增高;茯苓素对小鼠接触性皮肤过敏反应和移植排斥反应都有一定的抑制作用。
2.3对肠道菌群的调节作用;
给小鼠灌胃茯苓水提物检测小鼠粪便中双歧杆菌、乳杆菌、大肠杆菌和肠球菌的数量,结果表明,高剂量的茯苓能使肠道的双歧杆菌数量明显增加,说明茯苓对肠道菌群有良好的调节作用。
2.4保肝作用;
段会平等研究发现羧甲基茯苓多糖在细胞株培养中对HBsAg和HBeAG分泌有较好的抑制作用其治疗指数(TI)值为3.06和2.42,高于阿昔洛韦。陈春霞用羧甲基茯苓多糖100、200mg/kg/d给小鼠腹腔注射5d后,皮下注射四氯化碳花生油溶液,测得血清谷-丙转氨酶27.32%与41.03%,说明羧甲基茯苓多糖对肝损害具有保护作用;按100mg/kg/d剂量给大鼠肝部分切除手术前连续腹腔给药4d,手术后再连续腹腔给药3d,大鼠的肝再生度与再生肝重/体重分别增加73.29%和18.95%,说明羧甲基茯苓多糖具有促进肝细胞再生的作用。
2.5抗炎作用:
从茯苓提取液中分离出三萜化合物茯苓酸和去氢土莫酸,可以抑制TPA 引起的鼠耳肿胀,显示出良好的抗炎潜力。孙蕾在进行防己茯苓汤抗炎组分筛选及其机制分析过程中发现方剂中单味药茯苓能抑制激活巨噬细胞中亚硝酸盐含量,同时其乙醇提取物在高剂量对静息巨噬细胞具有一定的细胞毒性,这表明茯苓乙醇提取物体外具有较强抗炎活性。
建立二甲苯致小鼠急性炎症及无菌棉球致大鼠慢性炎症模型,给予茯苓多糖,结果显示,小剂量茯苓多糖可以抑制二甲苯所致的小鼠耳肿,并抑制棉球所致的大鼠皮下肉芽肿,研究表明,茯苓多糖对急慢性炎症反应具有抑制作用。茯苓具有药食两用的作用,除上述作用之外,茯苓还具有改善记忆力、抗惊厥等药理作用。由于茯苓具有利水消肿、增强免疫力、调节肠胃功能、护肝,同时具有一定抗炎作用,因而可以使得成长发育期的青少年除湿气、少生病、增强免疫力、增强胃肠功能、增强人体自我修复能力,从而有助于生长。
四、淮山药:
淮山药为薯蓣科多年生缠绕性藤本薯蓣(Dioscorea opposita Thunb.)的干燥根茎,始载于《神农本草经》,名薯蓣。《神农本草经》将其列为上品,称薯蓣“主伤中,补虚羸,除寒热邪气,补中益气力,长肌肉。”研究表明,淮山药及其有效成分具有广泛的药理作用。
1、淮山药化学成分;
淮山药块茎富含多糖、淀粉、维生素、氨基酸、矿物质及其它生物活性物质,是淮山药营养价值和活性作用的物质基础。
多糖为淮山药的主要活性成分,其调节免疫和抗氧化作用备受关注,研究表明淮山药多糖可通过增强小鼠淋巴细胞增殖能力,促进小鼠抗体生成和增强小鼠碳廓清能力实现免疫调节作用;而抗氧化和延缓衰老则是通过对抗自由基生成、清除自由基的方式发挥作用。薯蓣皂苷为淮山药的活性成分之一,主要为甾体皂苷类。研究表明,薯蓣皂苷具有调节免疫、抗炎镇痛、保护胃肠黏膜等多种药理作用。矿物元素是淮山药的重要营养成分。矿物元素作为人体生理活动所必需的物质,对人体正常生长发育有着极其重要的作用,是构成人体组织和维持正常生理活动的重要物质。其中,锌是淮山药中富含的一种矿物质,锌是RNA聚合酶和DNA聚合酶活化所需的必需元素,缺锌会造成人体发育迟滞,儿童缺锌会严重影响身体发育。
2、淮山药的药理作用:
2.1调节胃肠功能;
淮山药水煎剂,19.5克每公斤,39克每公斤,灌胃给药,增加利血平致脾气虚模型小鼠脑去甲肾上腺素(NE)、5-羟色胺(5-HT)。淮山药醇提物5克每公斤,10克每公斤,灌胃给药,抑制大黄治脾虚模型小鼠胃排空及肠管推动运动;体外抑制氯化乙酰胆碱及氯化钡引起的离体回肠强直性收缩;淮山药粥 (含淮山药4克每公斤)灌胃给药,增加食醋致脾虚模型大鼠体重、摄食量、活动次数、尿D-木糖,升高体温、改善便溏。淮山药生、制品粗多糖10克每公斤灌胃给药,抑制大黄致脾虚模型小鼠胃排空及小肠推进。
2.2增强免疫功能;
采用给予低铁饲料结合定量少量放血的方法建立缺血性贫血小鼠模型,检测给药前后血红蛋白(Hb)、红细胞计数(RBC)的变化。结果表明,淮山药多糖铁复合物具有较好的治疗缺铁性贫血作用。淮山药醇提液25克每公斤灌胃给药,增加小鼠玫瑰花形成细胞(RFC)脾细胞、T淋巴细胞数,促进溶血素生成。生药及麸炒品多糖灌胃给药,增加小鼠碳粒廓清指数K、增强单核巨噬细胞吞噬功能、提高溶血素。淮山药多糖0.05-0.8克每公斤灌胃给药,提高小鼠腹腔巨噬细胞吞噬百分率和吞噬指数,促进溶血素和溶血空斑形成,提高外周血t细胞增殖、nk细胞活性,促进淋巴细胞转化,增加血清IgG;提高黑色素b16或Lewis致癌细胞模型小鼠t淋巴细胞增值、nk细胞活性,增强脾脏细胞产生1L-2。淮山药水煎液灌胃给药,可提高氢化可的松致免疫机能低下小鼠脾系数、胸腺系数及耐缺氧能力。
五、枸杞子:
枸杞味甘,性平。主要归肝、肾、肺经。其甘补平和,质润多液,入肾可益精充髓助阳;走肝能补血明目;归肺以润肺止咳。凡肝肾不足和肺肾阴虚所致诸症,均可应用。为滋阴助阳,益精补血之良药。其化学成分主要含胡萝卜素、硫胺素、核黄素、烟酸、抗坏血酸、β-谷甾醇、亚油酸、玉蜀黍黄素、甜菜碱、酸浆果红素……及微量元素等。现代医学通过大量药理实验和临床实验证明,枸杞的确具有促进调节免疫功能、保肝功能,抗衰老功能及抗疲劳等药理作用。
1、枸杞子的营养成分;
现代研究分析表明,枸杞所含营养成份非常丰富,每百克枸杞果中含粗蛋白4.49克,粗脂肪2.33克,碳水化合物9.12克,类胡萝卜素96毫克,硫胺素 0.053毫克,核黄素0.137毫克,抗坏血酸19.8毫克,甜菜碱0.26毫克,还含有丰富的钾、钠、钙、镁、铁、铜、锰、锌等元素,以及22种氨基酸和多种维生素。
枸杞的营养成分丰富,是当今营养完全的天然原料。枸杞作为一种食品,分析表明枸杞子含有丰富的枸杞多糖、脂肪、蛋白质、游离氨基酸、牛磺酸、甜菜碱、枸杞子中含有大量的蛋白质、氨基酸、维生素和铁、锌、磷、钙等人体必需的养分,有促进和调节免疫功能,保肝和抗衰老3大药理作用,具有不可代替的药用价值。
2、枸杞子的药理作用:
2.1提高机体造血功能;
动物实验表明,给予正常小鼠及环磷酰胺造成白细胞受抑小鼠枸杞煎剂服用,结果显示小鼠的造血功能均得到一定的促进作用。枸杞子能增加小鼠外周血粒细胞的数目,有效促进股骨骨髓细胞的增殖及分化。
2.2调节神经系统功能;
枸杞子能保护机体的学习记忆,对抗理化因素造成的记忆损害症状。动物试验表明,给予小鼠右归丸水溶液,按照体重20mL/kg的剂量连续灌肠5d,能起到对抗部分记忆获得性障碍的作用。另外,枸杞子中含有较为丰富的胡萝卜素,而胡萝卜素在人体内能转化为维生素A,有效调节视神经,促进视网膜内视紫质的合成或再生,维持机体的正常视力。
2.3调节免疫作用;
枸杞子中含有的枸杞多糖能有效促进机体的免疫功能,对机体中的T淋巴细胞、B淋巴细胞有一定的激活作用,主要以增强细胞免疫为主,同时能增强机体的体液免疫功能。枸杞多糖对T淋巴细胞产生的免疫效应具有一定的选择性,给予低剂量的枸杞多糖能有效促进T淋巴细胞的转化,但高剂量对其转化有抑制作用,其具有免疫以及生物双向调节的作用。现代药学机制研究表明,枸杞子能提高机体呼吸系统的免疫功能,增强呼吸道疾病的防御能力,起到润肺效果。枸杞多糖的生物活性较强,能促进生物体内巨噬细胞的吞噬功能,而巨噬细胞能消灭有害细菌,通过吞噬有害微生物以及病原体对生物体的健康进行维护。
六、山楂:
山楂(Hawthorn)别名红果、棠棣、绿梨、北山楂,为蔷薇科植物山里红 Crataeguspinnatifida Bge var major N.E.Br.或山楂Crataegus pinnatifida Bge. 的干燥成熟果实,味酸、甘、微温、归脾、胃、肝经、具有消食健胃、行气散瘀、化浊降脂的功效。
药理作用分析:
1、胃肠道调节功能;
山楂对胃肠道运动功能具有一定的调节作用,能加强大鼠松弛状态胃平滑肌的收缩,而对乙酰胆碱及钡离子引起兔鼠离体胃肠道平滑肌收缩具有明显的抑制作用。山楂含多种有机酸,口服能增加胃中消化酶的分泌,增强脂肪酶、蛋白酶的活性。山楂还能促进肠道蠕动,对肠道功能紊乱有明显的双向调节作用, 有助于机械性和化学性消化。有报道称,口服山楂糖浆,治疗婴幼儿单纯性腹泻 212例,每次5~10m L,均获痊愈,有效率达100%。
2、增强免疫功能;
给家兔皮下注射山楂注射液,可使胸腺和脾的质量增加,血清溶菌酶含量、血清血凝抗体滴度及T淋巴细胞转化率均有明显提高,胸腺和脾脏与机体体液免疫和细胞免疫密切相关,表明山楂对体液免疫、细胞免疫均有一定的促进作用。
UA对环磷酰胺(CTX)造成的免疫低下小鼠具有保护作用,与模型组相比,UA 50、150、300mg·kg-1剂量组均能极显著增加腹腔巨噬细胞吞噬百分率 (P<0.001),且能显著提高免疫抑制小鼠的白细胞数;其中,低、中剂量的UA 对小鼠脾淋巴细胞的增殖和脾指数也有显著的增加作用(P<0.05),在高剂量虽对脾淋巴细胞的增殖和脾指数的增加有一定促进作用,但是作用差异无统计学意义(P>0.05)。
另外,山楂黄酮类主要成分金丝桃苷(Hyp)体内剂量在50mg·kg-1时对小鼠胸腺指数及脾T、B淋巴细胞增殖和腹腔巨噬细胞吞噬功能具有明显的增强作用;另外,Hyp体外剂量在100~6.25μg·m L-1时能显著促进脾T、B淋巴细胞的增殖和增强T淋巴细胞产生白细胞介素2(IL-2)的能力,同时也能提高腹腔巨噬细胞的吞噬功能和释放NO的能力。这表明一定浓度的Hyp在体内外具有增强免疫功能的作用。
3、抗菌作用;
山楂对多种杆菌和球菌有抵抗作用。李长青等研究以山楂核提取物为主要杀菌成分的皮肤消毒剂,对大肠肝菌、金黄色葡萄球菌、铜绿假单胞菌、白色念珠菌具有较好的杀菌效果,且稳定性较好。林玲用山楂榨取的原液对金黄色葡萄球菌、白色念珠菌、大肠杆菌等均有一定的抑制作用。
4、保护肝脏;
生山楂可降低高脂饲料所致SD大鼠肝组织丙二醛(MDA)、总胆固醇 (TC)等的含量,清除肝内堆积的三酰甘油,减少脂肪酸(FFA)对肝细胞毒性作用,使丙氨酸氨基转移酶(ALT)、天门冬酸氨基转移酶(AST)指标降低, 达到保肝作用。黄酮类化合物对多种原因引起的肝损伤具有显著的保护作用, 金丝桃苷也具有一定的改善肝功能的疗效。
七、麦冬:
麦冬是百合科植物麦冬Ophiopogon japonicus(Thunb)Ker-Gawl的干燥块根,其味甘、微苦、性微寒,入心、肺、胃经,具有滋阴益精、养阴益气、清心除烦、润肠通便等功效。目前,在麦冬的不同部位分离出甾体皂苷类、高异黄酮类、多糖类等成分。甾体皂苷和高异黄酮具有多种生物活性,是麦冬的主要活性部位。
麦冬药理作用:
1、增强免疫功能;
大量研究显示,麦冬多糖可以促进体液免疫和细胞免疫功能。麦冬多糖显著增加小鼠胸腺和脾脏的重量,增强小鼠网状内皮系统的吞噬能力,提高血清中溶血素含量,显示麦冬多糖具有良好的免疫增强和刺激作用。另外,麦冬多糖对分别以60Co-r射线全身照射和注射环磷酰胺造成小鼠免疫损伤有一定的恢复作用,能显著增加免疫低下小鼠的胸腺和脾脏重量,还能升高注射环磷酰胺小鼠的外周血白细胞数。
2、耐缺氧抗疲劳作用;
麦冬能提高皮下注射异丙肾上腺素的小鼠在低压缺氧条件下的存活数。麦冬煎剂、麦冬水提物、麦冬注射液皆有提高常压或减压小鼠的耐缺氧能力。小鼠游泳实验表明,麦冬氨基酸和麦冬多糖具有一定的抗疲劳作用。
3、改善肠胃功能;
石林林等研究麦冬多糖MDG-1对膳食诱导肥胖小鼠肠道益生菌群多样性的影响,发现MDG-1可在一定程度上增加小鼠肠道益生菌的数量,尤其是中国台湾乳杆菌和鼠乳杆菌,同时改善肠道菌群多样性,促进肠道益生菌的增殖。
王旭等发现麦冬多糖MDG-1可以改善肥胖小鼠的代谢紊乱,其作用机制可能与减少肝脏中胆固醇及胆汁酸的生物合成、增强酮体的生成有关。
八、熟地黄
熟地黄作为玄参科植物地黄块根,可通过蒸煮酒顿之法炮制而成。宋·苏颂编撰的《本草图经》中记载,其具有味甘,微温;归肝,肾经;能够补血滋阴,益精填髓;可用于治疗血虚,精血不足和肝肾阴虚等病症。其中通过现代药理学研究证实,熟地黄内含梓醇、糖类、地黄素、氨基酸、地黄苷(ABD等)以及多种化学微量元素,作用于人体可增强免疫能力,具有提高记忆力、促进造血、促进睡眠等的效果。
熟地黄药理作用;
1、促进造血及抗疲劳作用;
通过研究发现在实验鼠骨髓造血干细胞以及祖细胞的增殖分化过程通过熟地黄水提物的应用,能够快速增加血红蛋白及血红细胞数量增殖,加速造血恢复。业已表明,当熟地黄多糖所应用的剂量提高,其气血双虚模型小鼠自身外周血内含的细胞活性将得到显著提高,同时也将控制血清巨噬细胞的应激刺激,其中不同剂量用药效果观察证实,当属中等剂量效果最优。熟地黄多糖对不同血虚模型小鼠外周血象、骨髓有核细胞下降均有拮抗作用,对小鼠造血干细胞具有促进增值、分化作用,从而显示其补血功效。另有报道,放血与环磷酰胺并用所致气血双虚模型小鼠,熟地黄多糖可显著升高其红细胞、白细胞、血红蛋白、血小板水平,其中对白细胞、血小板提高作用最好,基本接近正常水平, 提示熟地黄多糖可显著改善模型小鼠的造血功能。
而在抗疲劳研究中发现,应用熟地黄水煎剂的试验小鼠在游泳体力完全消耗所花费的时间较常规小鼠来讲更长,研究证实,作为疲劳典型指标血清尿素氮和血乳酸对比分析中,通过熟地黄多糖应用效果可增加肝糖储留量,抑制血乳酸及尿素氮的生成。
2、增强机体的免疫力;
在白细胞介素-2(IL-2)、白细胞介素-4及干扰素-γ等免疫细胞研究中发现, 熟地黄内含多糖物质,能够极大的增强白血病活性增殖,提高淋巴细胞(胸腺、脾等位置)扩展释放,同时与用药剂量呈正相关;表明熟地黄在提升机体免疫功能具有明显作用,通过多糖活性物促进T淋巴细胞Th1和Th2细胞因子表达; A、D部位是熟地黄有效控制T细胞因子表达,降低分泌增殖效率的基础性环节。
采用水提醇沉提取熟地黄多糖,分别用绵羊红细胞(SRBC)和卵清蛋白为抗原给小鼠注射后,将熟地多糖分为3个剂量(50、100、200mg/kg·d)灌服小鼠7d,加强免疫后,检测到中剂量实验组SRBC抗体水平和卵清(P<0.05)抗体水平显著高于对照组(P<0.01),血清中白细胞介素-2(IL-2)激发水平显著高于对照组(P<0.05),表明熟地多糖对正常小鼠机体免疫有增强作用。研究发现, 熟地黄粗多糖可使胸腺皮质显著增厚,脾小结显著增大,胸腺皮质淋巴细胞数和脾淋巴细胞数显著增加,提示熟地黄粗多糖可显著改善模型小鼠的造血功能, 同时对免疫系统也有较好改善和刺激作用,也提示了熟地黄粗多糖是熟地黄促进造血和免疫功能的主要成分。
3、增强学习记忆能力;
熟地黄对于化学药品所致记忆障碍模型小鼠具有增强其学习记忆和空间记忆能力的作用,熟地黄能减少模型动物跳台训练期、测验期错误反应次数并延长测验期触电潜伏期;缩短模型小鼠寻找平台时间,并增加其垮台次数,其作用机制可能与改善中枢胆碱能神经系统功能,降低脑内Al3+含量,保护脑组织及维持脑内Glu/GABA的正常水平有关。崔瑛等采用谷氨酸单钠(MSG)毁损下丘脑弓状核模型作为肾阴虚学习记忆障碍模型,通过跳台法,Mirrio水迷宫法, 放免法观察,结果表明熟地黄能明显改善MSG大鼠被动回避和空间记忆能力, 抑制血浆CORT含量和海马GRmRNA表达,抑制基础体温升高,其机理与抑制血浆CORT含量和海马GRmRNA表达有关。研究表明,给予熟地黄的MSG大鼠,神经生长因子(NGF)、c-fos基因表达显著升高,学习记忆功能明显改善。我们认为熟地黄改善学习记忆作用机理可能与提高c-fos、NGF基因在海马的表达有关。
4、抗焦虑作用;
崔瑛等将昆明种小鼠分为对照组、地西洋组、熟地黄高、中、低剂量组,对照组每天灌胃生理盐水;地西泮组前4天每天灌胃生理盐水,后3天灌胃地西泮 2.5mg/(kg·d);熟地黄高、中、低剂量组灌胃熟地黄分别为12、8、4g/(kg·d),连续7天。7天后观察到熟地黄在小鼠明暗箱模型和小鼠高架十字模型上均表现出抗焦虑作用,其作用效果与地西泮相当。3个剂量组呈现神经药理特有的钟型曲线,初步显示熟地黄对小鼠焦虑行为有肯定的干预作用。实验发现,熟地黄有提高γ-氨基丁酸递质含量,增强γ-氨基丁酸A受体表达作用,与苯二氮卓类抗焦虑药有类似的作用途径,还发现熟地黄有抑制中枢谷氨酸递质含量和N-甲基-D-天冬氨酸受体1受体表达作用,这可能是熟地黄抗焦虑的又一作用途径。
5、促进红细胞新生;
久保道德以血流动态、皮下温度、自发运动量为指标,用不同浓度的干地黄50%乙醇提取物、熟地黄50%乙醇提取物分别灌胃给药,结果表明熟地黄对红细胞新生有明显的促进作用,对血虚所致的机体功能低下有改善作用。
6、中枢抑制作用;
崔豪等将昆明种小鼠分为对照组、地西洋组、熟地黄多糖组、熟地黄煎液组,通过小鼠自发活动实验、抗惊厥实验、镇静催眠实验,结果表明熟地黄煎液、熟地黄多糖均能够抑制小鼠的自发活动;缩短阈下剂量戊巴比妥钠诱导的小鼠睡眠潜伏期,延长睡眠时间;提示熟地黄煎液、熟地黄多糖对中枢神经系统具有抑制作用。
九、牡蛎;
牡蛎为牡蛎科动物长牡蛎(OstreaglgasThun-berg)、近江牡蛎(OstrearivularisGould)或大连湾牡蛎(OstrcatalienwhanensisCrosse)的贝壳,我国沿海一带均有分布,全年均可采收,生用或煅用,用时打碎。本品味咸、涩、微寒,归肝、肾经,有平肝潜阳、软坚散结、收敛固涩之功效,历代医书中都有对牡蛎的功能和主治的详细记载。近代研究表明:牡蛎含18种氨基酸、肝糖元、B族维生素、牛磺酸和钙、磷、铁、锌等营养成分,常吃可以提高机体免疫力。临床上,牡蛎可以治疗失眠。
1、改善记忆的功能;
牡蛎提取物中含有丰富的牛磺酸,牛磺酸是人体必需的非蛋白质氨基酸, 具有很重要的生物活性。在牛磺酸与脑发育关系的动物实验研究中发现,牛磺酸可促进大白鼠的学习与记忆能力。补充适量牛磺酸不仅可以提高学习记忆速度,而且还可以提高学习记忆的准确性,并且对神经系统的抗衰老也有一定作用。牛磺酸防治缺铁性贫血有明显效果,它不仅可以促进肠道对铁的吸收,还可增加红细胞膜的稳定性;牛磺酸还是人体肠道内双歧菌的促生因子,优化肠道内细菌群结构。
2、增强免疫力作用李氏采用血凝滴度测定牡蛎多糖抑制流感病毒在狗肾细胞(MDCK)中增殖的作用。
结果显示:牡蛎多糖能显著降低和抑制狗肾细胞培养流感病毒的血凝滴度。另有报道,李萌经研究发现,牡蛎糖胺聚糖(O-GAG)能显著降低Ⅰ型单纯疱疹病毒(HSV-1)感染小鼠的死亡率,延长其存活时间,并明显提高病毒感染小鼠的胸腺指数和脾指数,增强巨噬细胞吞噬能力。从而对Ⅰ型单纯疱疹病毒感染的小鼠具有一定的治疗作用并能提高小鼠的免疫功能。
3、补钙;
牡蛎含钙量丰富,主要含80%~95%碳酸钙成分。此外,还含有Zn、Mg、 P、Si、Fe、K等微量元素及少量的有机物。作为无机钙中的生物钙,经某些特殊处理后会更容易被人体吸收,为天然的钙源。
石丽霞等以牡蛎经传统明煅方法炮制后含有的钙离子在家兔体内的相对生物利用度为研究对象,以不同给药时间血清钙离子浓度的变化作为指标,使用传统药动学方法计算参数和相对生物利用度。结果表明,煅牡蛎中钙的相对生物利用度为142.5。李社花等对牡蛎锻制的最佳条件进行了优化,结果显示,牡蛎应在一定高温条件下煅制,才能保持牡蛎生品及煅制品的特有性质,同时利于粉碎和煎煮。
针对骨质疏松,牛煜等对补肾中药(牡蛎钙颗粒与补肾中药微粉1∶1混合) 进行研究,证实其可以使BMP-4蛋白表达提高,进而使骨形成增加。张永萍等用原子吸收分光光度法分别测定生龙骨、牡蛎壳,煅龙骨、牡蛎壳及其混合煎液中的微量元素。结果表明,各种煎煮液中含有8种微量元素,如锌、铜、锰等。牡蛎在补钙的同时,又能补充人体多种微量元素及氨基酸,同时也促进钙的吸收。
4、促进睡眠;
冯氏用桂枝加龙骨牡蛎汤治疗失眠18例。结果显示:患者的失眠、易惊、精力不足、记忆力减退等症状均有不同程度的改善。嘱患者每日1剂,水煎服, 15d为1个疗程,一般为1~2个疗程。结果:治愈13例,好转3例,无效2例,总有效率88%。另有报道,王氏用柴胡加龙骨牡蛎汤加减做为治疗组治疗顽固性失眠32例。每日1剂,水煎2次,早晚分服,连服14d。对照组给予西药安定片治疗,每次5mg,每晚睡前30min口服,连服14d。停药2周后,治疗组总有效率为90.6%,对照组总有效率为52.0%。提示治疗组远期治疗效果明显优于对照组,能够使睡眠持续改善。
十、胡萝卜:
胡萝卜属(Daucus Linnaeus)是伞形科(Umbelliferae)的一个属,全世界约有60种。胡萝卜栽培供蔬食用,亦入药。中医认为胡萝卜味甘,性平,有健脾和胃、补肝明目、清热解毒、壮阳补肾、透疹、降气止咳等功效。
胡萝卜素有“小人参”之称。胡萝卜富含糖类、脂肪、挥发油、胡萝卜素、维生素A、维生素B1、维生素B2、花青素、钙、铁等营养成分。其中胡萝卜含量较高。胡萝卜素进入人体内,在肠和肝脏可转变为维生素A,故亦称维生素A源,是膳食中维生素A的重要来源之一。维生素A有保护眼睛、促进生长发育、抵抗传染病的功能,是儿童与青少年不可缺少的维生素。
胡萝卜的功效:
1、益肝明目;
胡萝卜含有大量胡萝卜素,进入机体后,在肝脏及小肠粘膜内经过酶的作用,其中50%变成维生素A,有补肝明目的作用。
2、促进骨骼生长;
胡萝卜中的维生素A是骨骼正常生长发育的必需物质,有助于细胞增殖与生长,是机体生长的要素,对促进生长发育具有重要意义。
3、增强免疫功能;
胡萝卜素转变成维生素A,有助于增强机体的免疫功能,在预防上皮细胞病变的过程中具有重要作用,胡萝卜中的木质素也能提高机体免疫机制。
4、改善贫血;
胡萝卜素具有造血功能,能补充人体所需的血液,从而改善贫血或冷血症,同时含有丰富的钾。
5、杀菌、抗菌;
胡萝卜的芳香气味是挥发油造成的,能促进消化,并有杀菌作用。KilibardaVesna等对从胡萝卜(carrot)提取出的挥发油做抗菌实验表明,其对金黄色葡萄球菌(Staphylococcus aureus)、大肠杆菌(escherichia coli)有抑制作用。
6、改善认知功能障碍;
俞发荣通过药理实验证明胡萝卜的乙醇提取物通过其改善记忆、降低胆固醇和抗胆碱酯酶活性等多重作用改善认知功能障碍。
毒理学实验:
1、急性毒性试验;
应用小鼠进行急性毒性实验表明:小鼠灌胃本发明的辅助生长中药组合物,在246.8g/kg剂量下,给药后小鼠出现轻微活动减少,1小时左右恢复正常,给组合物后连续观察7天,无一动物死亡,其全身状况、饮食、摄水、小便和体重增长均正常,实验结果表明:小鼠灌胃本发明的辅助生长中药组合物的最大给药量为246.8g/kg/d(LD50>246.8g/kg)。本发明的辅助生长中药组合物每日临床用药总量为0.05g/kg/d;按体重计,小鼠灌胃本发明的辅助生长中药组合物的耐受量为人的4936倍。提示该辅助生长中药组合物急性毒性为零,临床用药安全。
2、长期毒性试验;
选用SD大鼠,给予不同浓度(9.0、3.0、1.0g/kg)的本发明的辅助生长中药组合物,每天灌胃一次,连续90天,末次给药后24小时各组活杀1/2动物(雌雄各半),其余1/2动物继续观察2周后活杀。试验期间观察动物的外观、一般行为、摄食量、体重变化,给药后90天和停药2周进行血液学(RBC、HB、网织红细胞、PLT、CT、WBC及分类)和血液生化(AST、ALT、ALP、Glu、 BUN、Crea、TP、T.BIL、ALB、CHOL)、尿液生化、脏器系数、病理组织学等指标检查。
试验结果表明:
本发明的辅助生长中药组合物在高、中、低剂量组动物一般状态良好,外观体征、行为活动、进食量和体重增长均无异常变化;三个剂量组及对照组血液学检查、血液生化学、尿液生化检查均在正常范围,组间无显著差异;各组主要脏器组织病理学检查未见明显异常。上述指标停药2周后也未见改变。本试验用量分别为临床用量的180、60、20倍,根据试验结果本发明的辅助生长中药组合物在高、中、低三个剂量(9.0、3.0、1.0g/kg)连续90天给药对大鼠无明显影响,无明确的毒性靶器官和敏感指标,恢复期观察也未见延迟性毒性反应,提示本发明的辅助生长中药组合物临床应用的剂量安全性较高。
3、动物局部刺激试验:
本发明辅助生长中药组合物皮肤过敏试验和片剂对大鼠直肠用量刺激性试验。
结果表明:皮肤过敏试验,高剂量组1g/kg、低剂量组0.1g/kg,分别相当于拟临床人用量(0.05g/kg)的20倍、2倍,经皮肤给药,均未见动物产生变态反应;直肠用药刺激性试验高剂量组6.25g/kg,低剂量组4.0g/kg,分别相当于拟临床人用量的125、80倍,在规定的时间内观察直肠粘膜均无充血、水肿等现象,病理组织学检查与空白对照组比较无明显差异,未见出现明显的刺激性反应,每组留存的部分动物其全身状况,体重、呼吸、循环、中枢神经系统及四肢活动等,均无明显异常反应。
案例1:
自2008年3月起至今,共为136例青少年使用辅助生长中药组合物,其中男性青少年58例,女性青少年78例,所有人员使用辅助生长中药组合物均有效果,所有人员的身高都超出医院拍片后给出的预测身高,有效率达到100%。所有人在服用的第一个月就有效果,男性青少年中超出预测身高最多的达到 17.0厘米,女性青少年中超出预测身高最多的达到13.1厘米。男性青少年平均超过预测身高8.6厘米,女性青少年平均超过预测身高10.3厘米。
案例2:
在一对李姓双胞胎姐妹身上做对比实验。从二人11岁起(当时妹妹测量身高为157.1厘米,姐姐测量身高为157.9厘米,二人身高差异不大),只给妹妹持续使用辅助生长中药组合物,未给姐姐使用辅助生长中药组合物。3年后,双胞胎姐妹的身高差为10厘米,妹妹身高183厘米,姐姐身高173厘米。
案例3:
女孩,袁某某,父亲身高170厘米,母亲身高156厘米。11岁时测量身高 156.3厘米,医院拍片后预测身高为163厘米左右。从11岁起持续使用辅助生长组合物,3年后,女孩身高长至174厘米,超过父亲身高。
案例4:
男孩,周某某,父亲身高174厘米,母亲身高162厘米,周某某12岁时测量身高为161.4厘米,医院拍片后预测身高为179厘米左右。从12岁起持续使用辅助生长组合物,4年后身高长至196厘米,比预测身高高出17厘米。
所述淮山药作为高营养食品含有大量蛋白质、糖类、B族维生素、维生素 C、维生素E、葡萄糖、粗蛋白氨基酸、胆汁碱、尿囊素、及碘、钙、铁、磷等人体不可缺少的无机盐和微量元素等营养成分。根据山东省农科院对淮山药的化验结果,其块茎中平均含粗蛋白质14.48%,粗纤维3.48%,淀粉43.7%,糖1.14%,钾2.62%,磷0.2%,钙0.2%,镁0.14%,灰分5.51%,铁 53.57ppm,锌29.22ppm,铜10.58ppm,锰5.38ppm。人类所需的18种氨基酸中,淮山药中含有16种。中医认为,淮山药“主伤中补虚,除寒热邪气,补中益气力,长肌肉,久服耳目聪明”。许多古典医籍都对淮山药作了很高的评价。
所述山楂具有助消化,益于心血管,抑菌。
所述枸杞子可保护肝脏,明目,增强造血,增强免疫力,抗疲劳。
所述麦冬生含有物碱、谷甾醇、葡萄糖、氨基酸、维生素等,具有抗疲劳、清除自由基、提高细胞免疫功能以及降血糖的作用。另外,麦冬有镇静、催眠、抗心肌缺血、抗心律失常、抗肿瘤等作用。
所述熟地黄可用于治疗形体消瘦、腰脊酸楚、脚软乏力等病症。
所述牡蛎中富含多种矿物质及微量元素,其中钙含量为40~94.04mg/g,铁为5.50~8.00mg/g,硒为49.00mg/g,锌为22.54mg/g,牡蛎提取物中牛磺酸含量为50.6mg/g。
所述胡萝卜富含糖类、脂肪、挥发油、胡萝卜素、维生素A、维生素B1、维生素B2、花青素、钙、铁等营养成分。
通过紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜的协同作用,可促进人体吸收,辅助适龄人群生长,无副作用,无不良反应,安全可靠。口感清淡,无不良臭味,使人易于接受,进而弥补西药有副作用的缺陷。
在一个实施例中,可选地,所述紫河车:1~20重量份,所述酸枣仁:1~ 20重量份,所述伏苓:1~22重量份,所述淮山药:1~22重量份,所述枸杞子:1~20重量份,所述山楂:1~20重量份,所述麦冬:1~20重量份,所述熟地黄:1~20重量份,所述牡蛎:1~21重量份,所述胡萝卜:1~25重量份。通过增加紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜的配比,可促进人体吸收,辅助适龄人群生长,无副作用,无不良反应,安全可靠。
在以上实施例中,可选地,所述紫河车:2~19重量份,所述酸枣仁:2~ 19重量份,所述伏苓:1.5~21重量份,所述淮山药:2~21.5重量份,所述枸杞子:1.5~19.5重量份,所述山楂:2~19重量份,所述麦冬:2~19.5重量份,所述熟地黄:1.4~19重量份,所述牡蛎:1.6~20重量份,所述胡萝卜:2~24 重量份。通过改进紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜的配比,可促进人体吸收,辅助适龄人群生长,无副作用,无不良反应,安全可靠。
在一个实施例中,可选地,所述紫河车:3~18重量份,所述酸枣仁:3~ 18重量份,所述伏苓:2~20重量份,所述淮山药:3~21重量份,所述枸杞子:2~19重量份,所述山楂:3~18重量份,所述麦冬:3~19重量份,所述熟地黄:2~18重量份,所述牡蛎:2~19重量份,所述胡萝卜:3~23重量份。通过改进紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜的配比,可促进人体吸收,辅助适龄人群生长,无副作用,无不良反应,安全可靠。
在以上实施例中,可选地,所述紫河车:4~19重量份,所述酸枣仁:4~ 19重量份,所述伏苓:3~19重量份,所述淮山药:4~20重量份,所述枸杞子:3~18重量份,所述山楂:4~17重量份,所述麦冬:4~18重量份,所述熟地黄:3~18.5重量份,所述牡蛎:3~18.6重量份,所述胡萝卜:4~22重量份。通过改进紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜的配比,可促进人体吸收,辅助适龄人群生长,无副作用,无不良反应,安全可靠。
在一个实施例中,可选地,所述紫河车:5~16重量份,所述酸枣仁:5~ 16重量份,所述伏苓:4~18重量份,所述淮山药:5~19重量份,所述枸杞子:4~17重量份,所述山楂:5~16重量份,所述麦冬:5~17重量份,所述熟地黄:4~17重量份,所述牡蛎:4~18重量份,所述胡萝卜:5~21重量份。通过改进紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜的配比,可促进人体吸收,辅助适龄人群生长,无副作用,无不良反应,安全可靠。
在以上实施例中,可选地,所述紫河车:6~15重量份,所述酸枣仁:6~ 15重量份,所述伏苓:5~17重量份,所述淮山药:6~18重量份,所述枸杞子:5~16.5重量份,所述山楂:6~15.5重量份,所述麦冬:5.5~16.5重量份,所述熟地黄:5~16重量份,所述牡蛎:5~17重量份,所述胡萝卜:6~19重量份。通过改进紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜的配比,可促进人体吸收,辅助适龄人群生长,无副作用,无不良反应,安全可靠。
在一个实施例中,可选地,所述紫河车:7~14重量份,所述酸枣仁:7~ 14重量份,所述伏苓:6~16重量份,所述淮山药:7~17重量份,所述枸杞子:6~16重量份,所述山楂:7~15重量份,所述麦冬:6~16重量份,所述熟地黄:6~15重量份,所述牡蛎:6~16重量份,所述胡萝卜:6~18重量份。通过改进紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜的配比,可促进人体吸收,辅助适龄人群生长,无副作用,无不良反应,安全可靠。
在以上实施例中,可选地,所述紫河车:8~13重量份,所述酸枣仁:8~ 13重量份,所述伏苓:6.5~15重量份,所述淮山药:7.5~16.5重量份,所述枸杞子:6.5~15.5重量份,所述山楂:7.5~14重量份,所述麦冬:6.5~15重量份,所述熟地黄:6.5~14.5重量份,所述牡蛎:7~15.4重量份,所述胡萝卜:6.5~17重量份。通过改进紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜的配比,可促进人体吸收,辅助适龄人群生长,无副作用,无不良反应,安全可靠。
在一个实施例中,可选地,所述紫河车:9~12重量份,所述酸枣仁:9~ 12重量份,所述伏苓:7~14重量份,所述淮山药:8~16重量份,所述枸杞子:7~15重量份,所述山楂:8~13重量份,所述麦冬:7~14重量份,所述熟地黄:7~14重量份,所述牡蛎:8~15重量份,所述胡萝卜:7~16重量份。通过改进紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜的配比,可促进人体吸收,辅助适龄人群生长,无副作用,无不良反应,安全可靠。
在以上实施例中,可选地,所述紫河车:9.5~11.5重量份,所述酸枣仁: 9.5~11.5重量份,所述伏苓:8~13重量份,所述淮山药:9~15重量份,所述枸杞子:8~13.5重量份,所述山楂:9~12重量份,所述麦冬:8~13重量份,所述熟地黄:8~13.4重量份,所述牡蛎:9~14重量份,所述胡萝卜:8~ 15重量份。通过改进紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜的配比,可促进人体吸收,辅助适龄人群生长,无副作用,无不良反应,安全可靠。
在一个实施例中,可选地,所述紫河车:10~11重量份,所述酸枣仁:10~ 11重量份,所述伏苓:9~12重量份,所述淮山药:10~14重量份,所述枸杞子:9~13重量份,所述山楂:10~11重量份,所述麦冬:9~12重量份,所述熟地黄:9~13重量份,所述牡蛎:10~13重量份,所述胡萝卜:9~13重量份。通过改进紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜的配比,可促进人体吸收,辅助适龄人群生长,无副作用,无不良反应,安全可靠。
在一个实施例中,可选地,所述紫河车:10.5重量份,所述酸枣仁:10.5 重量份,所述伏苓:11重量份,所述淮山药:12重量份,所述枸杞子:11重量份,所述山楂:10.5重量份,所述麦冬:11重量份,所述熟地黄:10重量份,所述牡蛎:11.5重量份,所述胡萝卜:12重量份。通过改进紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜的配比,可促进人体吸收,辅助适龄人群生长,无副作用,无不良反应,安全可靠。
参见图1,根据本申请的第二方面,提供了一种辅助生长的中药组合物的制备方法,包括以下步骤:
称取步骤:按照第一方面所述的组合物称取紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜;
清洗步骤:将所述紫河车、所述酸枣仁、所述伏苓、所述淮山药、所述枸杞子、所述山楂、所述麦冬、所述熟地黄、所述牡蛎和所述胡萝卜分别清洗备用;
烘干步骤:将清洗后的所述紫河车、所述酸枣仁、所述伏苓、所述淮山药、所述枸杞子、所述山楂、所述麦冬、所述熟地黄、所述牡蛎和所述胡萝卜分别进行烘干;其中,所述紫河车放入180-210℃的烘焙机里翻炒20-35分钟,直至烘干。
粉碎步骤:将烘干后的所述紫河车、所述酸枣仁、所述伏苓、所述淮山药、所述枸杞子、所述山楂、所述麦冬、所述熟地黄、所述牡蛎和所述胡萝卜分别进行粉碎;
混合步骤:将粉碎的所述紫河车、所述酸枣仁、所述伏苓、所述淮山药、所述枸杞子、所述山楂、所述麦冬、所述熟地黄、所述牡蛎和所述胡萝卜放到器皿中混合,形成混合粉;
过筛步骤:将所述混合粉放入100目筛去除大颗粒,获得标准粉。
包装步骤:将混合均一的所述标准粉包装成袋,进而包装成瓶销售,食用方便,在食用时将标准粉放入器皿中用水或果汁或牛奶调匀食用即可。
本申请的用于辅助生长的组合物,通过紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜的协同作用,可促进人体吸收,辅助适龄人群生长,无副作用,无不良反应,安全可靠,食用方便。
需要注意的是,除非另有说明,本申请使用的技术术语或者科学术语应当为本申请所属领域技术人员所理解的通常意义。
在本申请的描述中,需要理解的是,术语“中心”、“纵向”、“横向”、“长度”、“宽度”、“厚度”、“上”、“下”、“前”、“后”、“左”、“右”、“竖直”、“水平”、“顶”、“底”“内”、“外”、“顺时针”、“逆时针”、“轴向”、“径向”、“周向”等指示的方位或位置关系为基于附图所示的方位或位置关系,仅是为了便于描述本申请和简化描述,而不是指示或暗示所指的装置或元件必须具有特定的方位、以特定的方位构造和操作,因此不能理解为对本申请的限制。
此外,术语“第一”、“第二”等仅用于描述目的,而不能理解为指示或暗示相对重要性或者隐含指明所指示的技术特征的数量。在本申请的描述中,“多个”的含义是两个以上,除非另有明确具体的限定。
在本申请中,除非另有明确的规定和限定,术语“安装”、“相连”、“连接”、“固定”等术语应做广义理解,例如,可以是固定连接,也可以是可拆卸连接,或成一体;可以是机械连接,也可以是电连接;可以是直接相连,也可以通过中间媒介间接相连,可以是两个元件内部的连通或两个元件的相互作用关系。对于本领域的普通技术人员而言,可以根据具体情况理解上述术语在本申请中的具体含义。
在本申请中,除非另有明确的规定和限定,第一特征在第二特征“上”或“下”可以是第一和第二特征直接接触,或第一和第二特征通过中间媒介间接接触。而且,第一特征在第二特征“之上”、“上方”和“上面”可是第一特征在第二特征正上方或斜上方,或仅仅表示第一特征水平高度高于第二特征。第一特征在第二特征“之下”、“下方”和“下面”可以是第一特征在第二特征正下方或斜下方,或仅仅表示第一特征水平高度小于第二特征。
以上所述,仅为本申请较佳的具体实施方式,但本申请的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本申请揭露的技术范围内,可轻易想到的变化或替换,都应涵盖在本申请的保护范围之内。因此,本申请的保护范围应该以权利要求的保护范围为准。
Claims (9)
1.一种用于辅助生长的组合物,包括以下组分:
紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜。
2.根据权利要求1所述的用于辅助生长的组合物,其特征在于:
所述紫河车:1~20重量份;所述酸枣仁:1~20重量份;所述伏苓:1~22重量份;所述淮山药:1~22重量份;所述枸杞子:1~20重量份;所述山楂:1~20重量份;所述麦冬:1~20重量份;所述熟地黄:1~20重量份;所述牡蛎:1~21重量份;所述胡萝卜:1~25重量份。
3.根据权利要求1所述的用于辅助生长的组合物,其特征在于:
所述紫河车:3~18重量份;所述酸枣仁:3~18重量份;所述伏苓:2~20重量份;所述淮山药:3~21重量份;所述枸杞子:2~19重量份;所述山楂:3~18重量份;所述麦冬:3~19重量份;所述熟地黄:2~18重量份;所述牡蛎:2~19重量份;所述胡萝卜:3~23重量份。
4.根据权利要求1所述的用于辅助生长的组合物,其特征在于:
所述紫河车:5~16重量份;所述酸枣仁:5~16重量份;所述伏苓:4~18重量份;所述淮山药:5~19重量份;所述枸杞子:4~17重量份;所述山楂:5~16重量份;所述麦冬:5~17重量份;所述熟地黄:4~17重量份;所述牡蛎:4~18重量份;所述胡萝卜:5~21重量份。
5.根据权利要求1所述的用于辅助生长的组合物,其特征在于:
所述紫河车:7~14重量份;所述酸枣仁:7~14重量份;所述伏苓:6~16重量份;所述淮山药:7~17重量份;所述枸杞子:6~16重量份;所述山楂:7~15重量份;所述麦冬:6~16重量份;所述熟地黄:6~15重量份;所述牡蛎:6~16重量份;所述胡萝卜:6~18重量份。
6.根据权利要求1所述的用于辅助生长的组合物,其特征在于:
所述紫河车:9~12重量份;所述酸枣仁:9~12重量份;所述伏苓:7~14重量份;所述淮山药:8~16重量份;所述枸杞子:7~15重量份;所述山楂:8~13重量份;所述麦冬:7~14重量份;所述熟地黄:7~14重量份;所述牡蛎:8~15重量份;所述胡萝卜:7~16重量份。
7.根据权利要求1所述的用于辅助生长的组合物,其特征在于:
所述紫河车:10~11重量份;所述酸枣仁:10~11重量份;所述伏苓:9~12重量份;所述淮山药:10~14重量份;所述枸杞子:9~13重量份;所述山楂:10~11重量份;所述麦冬:9~12重量份;所述熟地黄:9~13重量份;所述牡蛎:10~13重量份;所述胡萝卜:9~13重量份。
8.根据权利要求1所述的用于辅助生长的组合物,其特征在于:
所述紫河车:10.5重量份;所述酸枣仁:10.5重量份;所述伏苓:11重量份;所述淮山药:12重量份;所述枸杞子:11重量份;所述山楂:10.5重量份;所述麦冬:11重量份;所述熟地黄:10重量份;所述牡蛎:11.5重量份;所述胡萝卜:12重量份。
9.一种用于辅助生长的组合物的制备方法,包括以下步骤:
称取步骤:按照权利要求1-8中任一项所述的组合物称取紫河车、酸枣仁、伏苓、淮山药、枸杞子、山楂、麦冬、熟地黄、牡蛎和胡萝卜;
清洗步骤:将所述紫河车、所述酸枣仁、所述伏苓、所述淮山药、所述枸杞子、所述山楂、所述麦冬、所述熟地黄、所述牡蛎和所述胡萝卜分别清洗备用;
烘干步骤:将清洗后的所述紫河车、所述酸枣仁、所述伏苓、所述淮山药、所述枸杞子、所述山楂、所述麦冬、所述熟地黄、所述牡蛎和所述胡萝卜分别进行烘干;
粉碎步骤:将烘干后的所述紫河车、所述酸枣仁、所述伏苓、所述淮山药、所述枸杞子、所述山楂、所述麦冬、所述熟地黄、所述牡蛎和所述胡萝卜分别进行粉碎;
混合步骤:将粉碎的所述紫河车、所述酸枣仁、所述伏苓、所述淮山药、所述枸杞子、所述山楂、所述麦冬、所述熟地黄、所述牡蛎和所述胡萝卜放到器皿中混合,形成混合粉;
过筛步骤:将所述混合粉放入100目筛去除大颗粒,获得标准粉。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910791605.XA CN112494597A (zh) | 2019-08-26 | 2019-08-26 | 用于辅助生长的组合物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910791605.XA CN112494597A (zh) | 2019-08-26 | 2019-08-26 | 用于辅助生长的组合物及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112494597A true CN112494597A (zh) | 2021-03-16 |
Family
ID=74923736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910791605.XA Pending CN112494597A (zh) | 2019-08-26 | 2019-08-26 | 用于辅助生长的组合物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112494597A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102813852A (zh) * | 2012-06-27 | 2012-12-12 | 陕西今正药业有限公司 | 一种具有促进生长发育的天然药食同源原料及其制备方法 |
-
2019
- 2019-08-26 CN CN201910791605.XA patent/CN112494597A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102813852A (zh) * | 2012-06-27 | 2012-12-12 | 陕西今正药业有限公司 | 一种具有促进生长发育的天然药食同源原料及其制备方法 |
Non-Patent Citations (3)
Title |
---|
《健康大讲堂》编委会: "《儿童长高食谱》", 31 January 2016, 黑龙江科学技术出版社 * |
玄华: "《全彩图解药物食物养生全书》", 30 April 2016, 北京联合出版公司 * |
谢文英: "《孩子吃得下、睡得香、不生病一本通》", 30 November 2015, 北京科学技术文献出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103652361B (zh) | 一种产后1-20天哺乳期母猪饲料及其制备方法 | |
CN103719498B (zh) | 一种提高免疫力的黄精保健茶及其制备方法 | |
CN102048933A (zh) | 一种治疗小儿腹泻的中药组合物及其制备方法 | |
CN103690919B (zh) | 用于治疗仔猪缺铁性贫血的药物及其制备方法 | |
CN108524814A (zh) | 一种用于降低血糖的中药组合物及其制备方法 | |
CN107853517B (zh) | 一种提神抗疲劳的中药饮料及其制备方法 | |
CN112546167A (zh) | 一种具有健脾利湿功能的中药组合物及其制备方法和应用 | |
CN1408397A (zh) | 含褪黑素和益智中药的组合物 | |
CN101946895B (zh) | 一种以泥鳅为主料的功能食品及其制备方法 | |
CN104225417A (zh) | 一种辅助改善记忆力功能的中药组合物及其制备方法 | |
CN104223297B (zh) | 一种延缓衰老的五味子保健口服液及其制备方法 | |
CN103610077A (zh) | 一种海参胶囊 | |
CN104489172A (zh) | 一种提高免疫力的刺五加保健茶及其制备方法 | |
CN106994141B (zh) | 一种治疗便秘的中药组合物及其制备方法 | |
CN103933450A (zh) | 一种预防或/和治疗胃肠疾病的中药组合物及其制备方法 | |
CN106177166A (zh) | 一种具有缓解体力疲劳功能的组合物及其制备方法 | |
CN112494597A (zh) | 用于辅助生长的组合物及制备方法 | |
KR101113593B1 (ko) | 홍삼, 천마 및 하수오 혼합 추출물을 유효 성분으로 하는 발기부전 질환의 예방과 치료를 위한 조성물 | |
CN102784230A (zh) | 一种治疗营养性贫血的药物组合物制剂 | |
CN107212402B (zh) | 降血压食品及其制备方法 | |
CN112273653A (zh) | 一种双向改善胃肠道功能、减肥美容谷物果蔬组合物 | |
CN111084878A (zh) | 一种用于肺及呼吸系统疾病的生物医药、医用全营养食品及制备方法 | |
CN100431585C (zh) | 一种健胸丰乳的中药制剂 | |
CN103705835A (zh) | 用于治疗僵猪的药物及其制备方法 | |
CN103689298B (zh) | 用于治疗僵猪的饲料及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210316 |